Current State and Perspective on Medical Treatment of Critical Leg Ischemia: Gene and Cell Therapy

@article{Emmerich2005CurrentSA,
  title={Current State and Perspective on Medical Treatment of Critical Leg Ischemia: Gene and Cell Therapy},
  author={J. Emmerich},
  journal={The International Journal of Lower Extremity Wounds},
  year={2005},
  volume={4},
  pages={234 - 241}
}
  • J. Emmerich
  • Published 2005
  • Medicine
  • The International Journal of Lower Extremity Wounds
Critical limb ischemia (CLI) is a severe disease associated with a high risk of amputation and mortality. In patients who cannot be revascularized, several medical options have been tested, including the use of prostanoids, spinal cord stimulation, and lumbar sympathectomy. None of these treatments has demonstrated a benefit on the amputation rates after 6 months of follow-up; these treatments cannot therefore be recommended for CLI treatment in patients forwhom surgery is not an option. In… Expand
Therapeutic Angiogenesis in the Management of Critical Limb Ischemia: Current Concepts and Review
TLDR
Although the optimal regimen of therapeutic angiogenesis has yet to be identified, building on the knowledge gained from the early pioneering studies may help to identify the best combination. Expand
Regenerative medicine in critical limb ischemia.
TLDR
How to develop optimal regenerative medicine concerning the selection of cell origin, cell type, combination with growth factor, and the influence of concomitant disease is discussed. Expand
A novel bFGF-GH injection therapy for two patients with severe ischemic limb pain
TLDR
Novel angiogenic therapy combined with nerve blocks seems to be a promising option in patients with severe pain, and parameters, such as skin surface temperature, transcutaneous oxygen partial pressure, and pain-free walking distance, were improved in both patients after the combined therapy. Expand
Bone marrow-derived mononuclear cell therapy induces distal angiogenesis after local injection in critical leg ischemia
TLDR
Bone marrow-derived mononuclear cell therapy in patients with critical leg ischemia induces an active, substained angiogenesis in the ischemic and distal parts of the treated limb, although this may not prevent amputation in some patients with very severe ischemIA. Expand
Application of autologous bone marrow mononuclear cells in six patients with advanced chronic critical limb ischemia as a result of diabetes: our experience.
TLDR
Limb salvage was possible in all six diabetic patients with Fontaine stage IV CLI following autologous BM MNC injection and the procedure was safe without any adverse outcomes. Expand
[Neurolitic block of the lumbar sympathetic chain improves chronic pain in a patient with critical lower limb ischemia].
TLDR
Neurolitic block of the lumbar sympathetic chain is an effective and safe treatment option for pain control in patients with critical limb ischemia patients in whom the only possible intervention would be limb amputation. Expand
Neurolitic block of the lumbar sympathetic chain improves chronic pain in a patient with critical lower limb ischemia
TLDR
Neurolitic block of the lumbar sympathetic chain is an effective and safe treatment option for pain control in patients with critical limb ischemia patients in whom the only possible intervention would be limb amputation. Expand
LA TERAPIA CELULAR EN EL TRATAMIENTO DE LA ISQUEMIA CRÍTICA DE EXTREMIDADES INFERIORES
TLDR
A review about the utilization of adult staminal cells in patients with critical limb ischaemia and the cellular therapy allows the possibility of dealing with diseases with the use alive cells. Expand
Clinical and Molecular Perspectives of Deep Tissue Injury: Changes in Molecular Markers in a Rat Model
TLDR
A rat model of DTI is established and the elevation of biochemical and molecular markers indicating muscle damage and regeneration, including creatine phosphokinase (CPK), hypoxia-inducible factor-1 (HIF-1), and Hedgehog (Hh) signaling molecules are presented. Expand
Multipotent adult progenitor cells sustain function of ischemic limbs in mice.
TLDR
Undifferentiated multipotent adult progenitor cells offer the potential to durably repair ischemic damage in peripheral vascular disease patients, unlike BMCs or vascular-committed progenitors. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 39 REFERENCES
Prostanoids for Chronic Critical Leg Ischemia
  • Annals of Internal Medicine
  • 1999
Chronic critical leg ischemia (referred to here as critical leg ischemia) is a late stage of atherosclerotic peripheral arterial disease characterized by pain at rest and trophic lesions of the lowerExpand
Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia.
TLDR
Intramuscular gene therapy with VEGF(165) for patients with chronic critical leg ischemia is safe, feasible, and effective. Expand
Spinal-cord stimulation in critical limb ischaemia: a randomised trial
TLDR
Spinal-cord-stimulation in addition to best medical care does not prevent amputation in patients with critical limb ischaemia in a randomised controlled trial. Expand
Spinal-cord stimulation in critical limb ischaemia: a randomised trial. ESES Study Group.
TLDR
Spinal-cord-stimulation in addition to best medical care does not prevent amputation in patients with critical limb ischaemia in a randomised controlled trial. Expand
Critical Limb Ischemia: Nothing To Give at the Office?
TLDR
Administration of alprostadil to patients with critical leg ischemia may yield short-term benefit, but the longer follow-up suggests that this apparent benefit is not sustained beyond the course of therapy. Expand
Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia.
TLDR
There is evidence to favour SCS over standard conservative treatment to improve limb salvage and clinical situation in patients with NR-CCLI. Expand
The effectiveness of percutaneous transluminal angioplasty for the treatment of critical limb ischemia: a 10-year experience.
TLDR
PTA is a feasible, safe, and effective procedure for the treatment of CLI and the high limb salvage rate is attributed to the high assisted primary and secondary patency rates despite the low primary patency rate. Expand
A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease.
TLDR
Iloprost has significant (p < 0.05) beneficial effects over placebo on ulcer healing and pain relief, but these were relatively soft endpoints to study when side effects may have unblinded many observers and patients. Expand
A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease.
TLDR
Iloprost has significant (p < 0.05) beneficial effects over placebo on ulcer healing and pain relief, but these were relatively soft endpoints to study when side effects may have unblinded many observers and patients. Expand
Management of peripheral vascular disease.
TLDR
Given that PAD is a powerful indicator of systemic atherosclerosis and (independent of symptoms) is associated with an increased risk of myocardial infarction and stroke, as well as a six times greater likelihood of death, the prevalence and demographic distribution of measurable PAD becomes particularly relevant. Expand
...
1
2
3
4
...